Frost & Sullivan: Pharma Industry Reset

Frost & Sullivan released a new analysis, 'Growth Opportunities in Global Pharmaceutical Industry, 2026', detailing a profound transformation in the pharmaceutical sector. The report highlights that traditional success drivers are being replaced by new competitive imperatives focused on execution excellence, supply resilience, and AI-enabled operations. Key themes include policy reforms, accelerating patent expiries, and intensifying pricing pressures, which are compressing value-capture windows. Deliverability is emerging as a critical competitive advantage, with manufacturing readiness and cold-chain integrity being essential differentiators. Innovation models are evolving, with companies prioritizing scalable assets and integrating external innovation. Supply resilience has become a strategic imperative due to geopolitical uncertainty. Artificial intelligence is moving into audit-ready workflows across various functions. Growth opportunities are concentrated around Biopharmaceutical and next-generation modalities, including GLP-1 receptor agonist, Antibody–drug conjugate, Radionuclide therapy, and Cell and gene therapy. The study forecasts a divergence in growth, with Biopharmaceutical expanding market share while small molecules remain the cash-flow backbone. Abhi Gupta, Industry Principal at Frost & Sullivan, emphasized the need for organizations to rebuild operating models around resilience, speed, disciplined innovation, and scalable execution to thrive.